A new approach to prevent vascular and diabetic limb amputations.

Our approach

Turning an emerging therapy into an accessible device.

BlueHealer is in active preclinical development. The specifics of how the device works are in stealth, but our direction is clear.

1. 01

   The biology: distraction osteogenesis-induced angiogenesis

   Ilizarov's Law of Tension-Stress established that gradual, sustained mechanical tension on living tissue stimulates active regeneration. When cortical bone is slowly distracted, that tension triggers distraction osteogenesis — and critically, induces a parallel angiogenic response. New blood vessels form and extend into the surrounding soft tissue, restoring perfusion to ischemic regions. Applied transversely in the tibia, this biological mechanism becomes a tool for treating chronic limb-threatening ischemia from the inside out.

2. 02

   A rapidly growing global therapy

   TTT is now being performed in more than 20 countries as an adjunct therapy for the most complex limb salvage and reconstruction cases — alongside, not instead of, existing options like bypass grafting and endovascular intervention. Surgeons across North America, Europe, and beyond are reporting remarkable wound healing and limb preservation outcomes in patients previously told amputation was inevitable. The field is growing rapidly.

3. 03

   The gap: why a better device is needed

   Current approaches rely on external fixation frames, introducing infection risk, poor patient tolerance, and limited adoption outside specialized centers. BlueHealer is developing a next-generation device to address these barriers — making the therapy more accessible, controllable, and feasible for broader surgical adoption. Device details are in stealth.